Redirecting to http://dergipark.org.tr/_fragment?_hash=hyI5jUYgZflV9MQPckpYda3QzZGv3P77DfdA1-Xa7KA&_path=id%3D815093%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Research Article
BibTex RIS Cite

Epidemiological and overall survival characteristics of prostate cancer in Ege University hospital database

Year 2020, Volume: 59 Suppl: 1 (Oncology), 33 - 39, 26.10.2020

Ayfer Haydaroğlu Banu Sarsık Kumbaracı Deniz Yalman Serdar Özkök Oktay Nazlı Bülent Semerci Erdal Apaydın Barış Altay Burak Turna Adnan Şimşir Erhan Gökmen Ulus Şanlı Bülent Karabulut Sait Şen Fatma Sert Özgür Ömür Fuat Kızılay Serdar Kalemci

https://doi.org/10.19161/etd.815093

Abstract

Aim: The aim of this study is to evaluate the epidemiological, treatment modality and survival characteristics of 4792 patients with Prostate Cancer(PC) who were treated at Ege University Hospital (EUH).

Methods and Materials: The data were recorded using the CANREG programme. WHO (World Health Organization) and SEER (Surveillance, Epidemiolgy, and End Results) system were considered for classification and survival analysis. Chi-square test, General Linear Model and Kaplan-Meier survival analysis were done. Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and Tarone-Ware models were used for Kaplan-Meier survival analyses. p value <0.05 was considered significant.


Results: Data of 4792 PC patients were analysed. PC was mostly seen in the age group of 60-69 years. Most common histological type was “acinary adenocarcinoma”. Localized disease was most common (61,2%) among patients who could be staged. There is a linear increase in prostate cancer according to years. There is a linear increase in mortality until 2008, then decrease afterwards. Median survival was 120 months. Five and 10-year overall survival (OS) rates were 74.2% and 55.2% respectively. Five-year OS rates for localized, locally advanced and metastatic disease were 86.3%, 78.1% and 21.7% respectively whereas 10-year OS rates were 70%, 62.7% and 14% respectively. Survival rates differ significantly in patients who were treated for localized and locally advanced disease while the difference disappeared for metastatic disease.

Conclusions: This is the largest prostate cancer data of a single center in Turkey with 4792 cases registered at EUH Cancer Database. Five and 10 year-OS rates were 74.2% and 55.2% respectively. Survival rates differ significantly in patients who were treated for localized and locally advanced disease while the difference disappeared for metastatic disease.

Keywords

Prostate cancer epidemiology incidence mortality survival

References

  • Jemal A, Vineis P, Bray F, Torre L, Forman D (Editörler). Kanser Atlası. İkinci Baskı. Atlanta, GA: Amerikan Kanser Derneği; 2014. www.cancer.org/canceratlas
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin 2018;68(1):7–30.
  • Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-87.
  • Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6):1079–92.
  • Gültekı̇n M, Boztaş G. Türkı̇ye Kanser İstatı̇stı̇klerı̇. TC Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.
  • Wong MC, Goggins WB, Wang HH et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 2016;70(5):862-74.
  • Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018;25(6):524-31.
  • Jeong CW, Washington SL 3rd, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. The new Surveillance, Epidemiology, and End Results prostate with watchful waiting database: Opportunities and limitations. Eur Urol 2020;21. pii: S0302-2838(20)30045-2.
  • Tınay İ, Türkeri L. Lokalize prostat kanserinde aktif izlem seçeneği. Üroonkolojı̇ Bültenı̇ 2012;11(2): 114-18.
  • van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54(6): 1297-305.
  • Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010;58(6):831-35.
  • Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 2011; 29(16):2185-90.
  • Klotz L, Zhang L, Lam A ve ark. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
  • Knipper S, Pecoraro A, Palumbo, C et al: The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes Control 2020;31(3):283-90

Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel sağkalım özellikleri

Year 2020, Volume: 59 Suppl: 1 (Oncology), 33 - 39, 26.10.2020

Ayfer Haydaroğlu Banu Sarsık Kumbaracı Deniz Yalman Serdar Özkök Oktay Nazlı Bülent Semerci Erdal Apaydın Barış Altay Burak Turna Adnan Şimşir Erhan Gökmen Ulus Şanlı Bülent Karabulut Sait Şen Fatma Sert Özgür Ömür Fuat Kızılay Serdar Kalemci

https://doi.org/10.19161/etd.815093

Abstract

Amaç: Ege Üniversitesi (EÜ) Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan prostat kanseri (PK) tanılı 4792 hastanın epidemiyolojik özellikleri, tedavi modaliteleri ve sağkalım özelliklerinin tanımlanması amaçlanmıştır.

Gereç ve Yöntem: EÜ Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan PK verileri CANREG özel bilgisayar programına kaydedilmiş, DSÖ (Dünya Sağlık Örgütü) ve SEER (Surveillance, Epidemiolgy, and End Results) sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistiksel analizlerde Kikare, General Linear Model, Kaplan Meier sağkalım analizleri uygulanmıştır. Kaplan-Meier Sağkalım analizinde Log Rank(Mantel-Cox), Breslow(Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistiksel analizlerde p<0,05 değeri anlamlı kabul edilmiştir.

Bulgular: PK tanılı 4792 hasta verisi analiz edilmiştir. Olgularımızda PK’ne en çok 60-69 yaş grubunda rastlanmaktadır. Histopatolojik olarak en sık “asiner adenokarsinom” görülmektedir. Evrelendirme çalışması yapılabilen PK’lerinde lokalize dönemin %61,2 oran ile en fazla olduğu saptanmıştır. PK’lerinin görülüşünde yıllara göre doğrusal bir artış dikkat çekmektedir. Mortalitede ise 2008’e kadar doğrusal artış daha sonra azalış vardır. PK olgularımızda ortanca genel sağkalım(GSK) 120 aydır, tüm olgular için 5 ve 10 yıllık GSK’lar %74,2 ve %55,2 bulunmuştur. Beş yıllık GSK oranları lokalize, lokal ileri ve metastatik evrelerde sırasıyla %86,3, %78,1 ve %21,7 saptanırken 10 yıllık GSK için sırasıyla %70, %62,7 ve %14’dür. Lokal ve lokal ileri evrelerde tedavi alanlarda sağkalımlarda anlamlı bir fark elde edilirken metastatik evrede anlamlı sonuç kaybolmaktadır.

Sonuç: EÜ Hastanesi Kanser veri tabanında bulunan 4792 PK’li bu seri tek merkez olarak Türkiye’deki en geniş PK serisidir. PK olgularımızda 5 ve 10 yıllık GSK oranları sırasıyla %74,2 ve %55,2 bulunmuştur. Evrelere göre tedavilerin GSK’lar üzerine katkıları lokal ve lokal ileri evrede anlamlı bulunurken metastatik evrede bu anlamlılık kalmamaktadır.

Keywords

Prostat Kanseri Epidemiyoloji, Mortalite, Sağkalım

References

  • Jemal A, Vineis P, Bray F, Torre L, Forman D (Editörler). Kanser Atlası. İkinci Baskı. Atlanta, GA: Amerikan Kanser Derneği; 2014. www.cancer.org/canceratlas
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin 2018;68(1):7–30.
  • Ferlay J, Colombet M, Soerjomataram I et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-87.
  • Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6):1079–92.
  • Gültekı̇n M, Boztaş G. Türkı̇ye Kanser İstatı̇stı̇klerı̇. TC Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.
  • Wong MC, Goggins WB, Wang HH et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 2016;70(5):862-74.
  • Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018;25(6):524-31.
  • Jeong CW, Washington SL 3rd, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. The new Surveillance, Epidemiology, and End Results prostate with watchful waiting database: Opportunities and limitations. Eur Urol 2020;21. pii: S0302-2838(20)30045-2.
  • Tınay İ, Türkeri L. Lokalize prostat kanserinde aktif izlem seçeneği. Üroonkolojı̇ Bültenı̇ 2012;11(2): 114-18.
  • van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54(6): 1297-305.
  • Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010;58(6):831-35.
  • Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 2011; 29(16):2185-90.
  • Klotz L, Zhang L, Lam A ve ark. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
  • Knipper S, Pecoraro A, Palumbo, C et al: The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes Control 2020;31(3):283-90
There are 15 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Research Articles
Authors

Ayfer Haydaroğlu 0000-0001-5709-0981

Banu Sarsık Kumbaracı 0000-0003-4775-3942

Deniz Yalman 0000-0002-4010-8353

Serdar Özkök 0000-0001-6546-5368

Oktay Nazlı 0000-0001-8500-5510

Bülent Semerci 0000-0002-5986-3869

Erdal Apaydın 0000-0003-0653-3900

Barış Altay 0000-0002-3101-8022

Burak Turna 0000-0002-3548-2236

Adnan Şimşir 0000-0002-0681-0325

Erhan Gökmen 0000-0003-4596-2986

Ulus Şanlı 0000-0002-0062-6105

Bülent Karabulut 0000-0002-1949-8334

Sait Şen 0000-0002-1100-6657

Fatma Sert 0000-0001-6052-8614

Özgür Ömür 0000-0002-5128-9620

Fuat Kızılay 0000-0003-1856-0404

Serdar Kalemci 0000-0002-9629-5258

Publication Date October 26, 2020
Submission Date August 28, 2020
Published in Issue Year 2020 Volume: 59 Suppl: 1 (Oncology)

Cite

Vancouver Haydaroğlu A, Sarsık Kumbaracı B, Yalman D, Özkök S, Nazlı O, Semerci B, et al. Ege Üniversitesi hastanesinde prostat kanserlerinin epidemiyolojisi ve genel sağkalım özellikleri. EJM. 2020:33-9.
 Download Cover Image